Morphinsulfat Hameln (Morphine Sulfate)

Morphine sulfate, the active ingredient in Morphinsulfat Hameln, is an opioid analgesic presented as a sterile injectable for epidural, intramuscular and intrathecal use. It is employed to treat severe acute pain, post‑operative pain and labor analgesia in adult patients requiring potent central nervous system analgesia.

GNH USA supplies Morphinsulfat Hameln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Morphine sulfate is an opioid analgesic used in the management of severe pain conditions that require potent central nervous system activity.

- Severe acute pain: delivers strong analgesia for injuries or medical emergencies where rapid pain relief is needed. - Post‑operative pain: administered after surgery to control moderate to severe pain during the recovery period. - Labor analgesia: provided via epidural or intrathecal routes to relieve pain during childbirth while maintaining maternal consciousness.

Common Side Effects: - Nausea - Constipation - Drowsiness - Itching

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Allergic reaction (anaphylaxis)

Morphinsulfat Hameln should be used with careful clinical monitoring and adherence to controlled substance regulations. - Assess respiratory function: monitor for signs of depression, especially after dose changes. - Evaluate renal and hepatic function: adjust use in impairment. - Avoid use with other CNS depressants: increased risk of sedation and respiratory effects. - Pregnancy and lactation: use only if benefits outweigh risks; consult obstetric specialist. - Monitor for dependence and abuse: follow controlled substance guidelines. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Morphine sulfate may interact with several drug classes, requiring vigilance to avoid additive effects.

Major Interactions (Avoid): - Concurrent use with other opioids: additive respiratory depression. - Benzodiazepines or barbiturates: heightened central nervous system depression. - MAO inhibitors: risk of severe hypotension and serotonin syndrome.

Moderate Interactions (Monitor Closely): - SSRIs: possible serotonin syndrome. - Anticholinergic agents: may worsen constipation. - Diuretics: may increase risk of hypotension.